Targeting SARS-CoV-2 NSP14 with TDI-015051: a new frontier in antiviral therapy

Guoxiang Li1, Yiran Wu2, Fangfang Zhou3

  • 1The First Affiliated Hospital, the Institutes of Biology and Medical Sciences, Suzhou Medical College, Soochow University, Suzhou 215000, China; Life Sciences Institute and State Key Laboratory of Transvascular Implantation Devices of the Second Affiliated Hospital of the Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310000, China.

Science Bulletin
|April 22, 2025
PubMed
Abstract

No abstract available in PubMed .